Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT00082836
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • yttrium Y 90 ibritumomab tiuxetan — RADIATION

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This clinical trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with recurrent primary CNS lymphoma.

Key Dates

Start date
Dec 31, 2004
Status verified
Jan 2013
Primary completion
May 31, 2007

Study Design

Enrollment
10 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Dosimetry at 1, 24, and 48 hours

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan - Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in New York, NY

By research site
Memorial Sloan - Kettering Cancer Center· New York, NY

Related Studies